-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Except for no hair on the head, it is everywhere!" Behind the jokes are the anxiety and unspeakable pain of countless people suffering from hair loss.
Alopecia areata (AA) is the second highest incidence of hair loss in the world.
Today, Eli Lilly and Incyte announced that their JAK inhibitor baricitinib has achieved positive results in the second phase 3 clinical trial BRAVE-AA1 for the treatment of patients with severe alopecia areata.
Baritinib is an oral JAK inhibitor that has been approved by the FDA for the treatment of rheumatoid arthritis.
In the randomized, double-blind, placebo-controlled clinical trial BRAVE-AA1, the proportion of adult patients with severe alopecia who received baritinib (dose 4 mg) for 36 weeks after reaching a scalp hair coverage rate of more than 80% was 35%, significantly better than the placebo group (5%).
These data are consistent with the results of the Phase 3 clinical trial BRAVE-AA2 announced earlier this year.
Reference materials:
Reference materials:[1] Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study Retrieved April 20, 2020, https://investor.
[1] Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study Retrieved April 20, 2020, https://investor.
[2] Have you caught the trouble of "bald"? Retrieved December 27, 2020, from
[3] Olamiju et al.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
